MKI67 and breast carcinoma: From a clinical viewpoint, owing to the varying objectivity of pathologists and different qualities of antibodies to ER, PR, HER-2 and Ki-67 used in immunohistochemical methods, determining the molecular subtype for an individual’s breast cancer may be influenced by subjective and objective factors.